Flavoxate

Chemical compound
  • G04BD02 (WHO)
Identifiers
  • 2-(1-piperidyl)ethyl 3-methyl-4-oxo-2-phenylchromene-8-carboxylate
CAS Number
  • 15301-69-6 checkY
PubChem CID
  • 3354
IUPHAR/BPS
  • 7187
DrugBank
  • DB01148 checkY
ChemSpider
  • 3237 checkY
UNII
  • 3E74Y80MEY
KEGG
  • D07961 checkY
ChEBI
  • CHEBI:5088 checkY
ChEMBL
  • ChEMBL1493 ☒N
CompTox Dashboard (EPA)
  • DTXSID3023053 Edit this at Wikidata
ECHA InfoCard100.035.745 Edit this at WikidataChemical and physical dataFormulaC24H25NO4Molar mass391.467 g·mol−13D model (JSmol)
  • Interactive image
  • O=C(OCCN1CCCCC1)c4cccc2c4O/C(=C(\C2=O)C)c3ccccc3
InChI
  • InChI=1S/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3 checkY
  • Key:SPIUTQOUKAMGCX-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Flavoxate is an anticholinergic with antimuscarinic effects. Its muscle relaxant properties may be due to a direct action on the smooth muscle rather than by antagonizing muscarinic receptors.

Clinical uses

Flavoxate is used to treat urinary bladder spasms. It is available under the trade name Urispas (Paladin)(india), Genurin (by Recordati, Italy) in Italy and KSA, Uritac by El Saad company in Syria, under the name Bladderon by Nippon Shinyaku of Japan, or Bladuril in Chile, Utispas ( Apex Pharma) in Nepal.

Flavoxate is indicated for symptomatic relief of interstitial cystitis, dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis.

Side effects

Flavoxate is generally well tolerated, but can potentially cause vomiting, upset stomach, dry mouth or throat, blurred vision, eye pain,[1] and increased sensitivity of the eyes to light.

Contraindications

Flavoxate is contraindicated in patients who have any of the following obstructive conditions: pyloric or duodenal obstruction, obstructive intestinal lesions or ileus, achalasia, gastrointestinal hemorrhage and obstructive uropathies of the lower urinary tract.

References

  1. ^ Mohammed ZS, Simi ZU, Tariq SM, Ali KR (November 2008). "Bilateral acute angle closure glaucoma in a 50 year old female after oral administration of flavoxate". British Journal of Clinical Pharmacology. 66 (5): 726–7. doi:10.1111/j.1365-2125.2008.03254.x. PMC 2661991. PMID 18754848.

Further reading

  • Brenner GN (2000). Pharmacology. Philadelphia, PA: W.B. Saunders Company. ISBN 0-7216-7757-6.
  • Canadian Pharmacists Association (2000). Compendium of Pharmaceuticals and Specialties (25th ed.). Toronto, ON: Webcom. ISBN 0-919115-76-4.
  • "Flavoxate". PubMed Health. U.S. National Library of Medicine, National Institutes of Health.
  • v
  • t
  • e
Psychedelics
(5-HT2A
agonists)
Benzofurans
Lyserg‐
amides
Phenethyl‐
amines
2C-x
25x-NBx
25x-NB
25x-NB3OMe
  • 25B-NB3OMe
  • 25C-NB3OMe
  • 25D-NB3OMe
  • 25E-NB3OMe
  • 25H-NB3OMe
  • 25I-NB3OMe
  • 25N-NB3OMe
  • 25P-NB3OMe
  • 25T2-NB3OMe
  • 25T4-NB3OMe
  • 25T7-NB3OMe
  • 25TFM-NB3OMe
25x-NB4OMe
  • 25B-NB4OMe
  • 25C-NB4OMe
  • 25D-NB4OMe
  • 25E-NB4OMe
  • 25H-NB4OMe
  • 25I-NB4OMe
  • 25N-NB4OMe
  • 25P-NB4OMe
  • 25T2-NB4OMe
  • 25T4-NB4OMe
  • 25T7-NB4OMe
  • 25TFM-NB4OMe
25x-NBF
25x-NBMD
  • 25B-NBMD
  • 25C-NBMD
  • 25D-NBMD
  • 25E-NBMD
  • 25F-NBMD
  • 25H-NBMD
  • 25I-NBMD
  • 25P-NBMD
  • 25T2-NBMD
  • 25T7-NBMD
  • 25TFM-NBMD
25x-NBOH
25x-NBOMe
Atypical structures
25x-NMx
  • 25B-NMe7BF
  • 25B-NMe7BT
  • 25B-NMe7Bim
  • 25B-NMe7Box
  • 25B-NMe7DHBF
  • 25B-NMe7Ind
  • 25B-NMe7Indz
  • 25B-NMePyr
  • 25I-NMe7DHBF
  • 25I-NMeFur
  • 25I-NMeTHF
  • 25I-NMeTh
N-(2C)-fentanyl
  • N-(2C-B) fentanyl
  • N-(2C-C) fentanyl
  • N-(2C-D) fentanyl
  • N-(2C-E) fentanyl
  • N-(2C-G) fentanyl
  • N-(2C-H) fentanyl
  • N-(2C-I) fentanyl
  • N-(2C-IP) fentanyl
  • N-(2C-N) fentanyl
  • N-(2C-P) fentanyl
  • N-(2C-T) fentanyl
  • N-(2C-T-2) fentanyl
  • N-(2C-T-4) fentanyl
  • N-(2C-T-7) fentanyl
  • N-(2C-TFM) fentanyl
3C-x
4C-x
DOx
HOT-x
MDxx
Mescaline (subst.)
TMAs
  • TMA
  • TMA-2
  • TMA-3
  • TMA-4
  • TMA-5
  • TMA-6
Others
Piperazines
Tryptamines
alpha-alkyltryptamines
x-DALT
x-DET
x-DiPT
x-DMT
x-DPT
Ibogaine-related
x-MET
x-MiPT
Others
Others
Dissociatives
(NMDAR
antagonists)
Arylcyclo‐
hexylamines
Ketamine-related
PCP-related
Others
Adamantanes
Diarylethylamines
Morphinans
Others
Deliriants
(mAChR
antagonists)
Others
Cannabinoids
(CB1 agonists)
Natural
Synthetic
AM-x
CP x
HU-x
JWH-x
Misc. designer cannabinoids
D2 agonists
GABAA
enhancers
Inhalants
(Mixed MOA)
κOR agonists
Oneirogens
Others
  • v
  • t
  • e
mAChRsTooltip Muscarinic acetylcholine receptors
Agonists
Antagonists
Precursors
(and prodrugs)
See also
Receptor/signaling modulators
Nicotinic acetylcholine receptor modulators
Acetylcholine metabolism/transport modulators